Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Crestone Inc. is currently handling 1 pending office action in the Biotechnology & Pharmaceuticals technology area. This action is assigned to 1 distinct examiner, CHONG, YONG SOO, who is also the busiest examiner for the company. The prosecution is further concentrated within 1 distinct art unit, meaning all current office activity is localized to a single technical group and a single reviewer. With 1 pending office action and a busiest examiner pending count of 1, CHONG, YONG SOO is the sole individual managing the company's active applications.
This lack of diversification across examiners or art units means the company's immediate prosecution success relies entirely on the outcome of this 1 pending office action. Practitioners should focus on the specific examiner's history, as there are no other distinct examiners or art units to consider in the current portfolio. The 1 distinct art unit provides a narrow but focused environment for these proceedings. The outcome of this Biotechnology & Pharmaceuticals matter will be the primary indicator of the company's current success at the patent office.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| CHONG, YONG SOO | 1 | 43.8% | +41.8% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18038401 | METHODS AND COMPOUNDS FOR TREATMENT OF AUTISM SPECTRUM DISORDER | CHONG, YONG SOO | 27d |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18038401 | METHODS AND COMPOUNDS FOR TREATMENT OF AUTISM SPECTRUM DISORDER | CHONG, YONG SOO | 27d |
| Art Unit | Apps |
|---|---|
| 1623 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18038401 | METHODS AND COMPOUNDS FOR TREATMENT OF AUTISM SPECTRUM DISORDER | CHONG, YONG SOO | 1623 | §102§103§112 | Non-Final OA | 27d | Pending | May 23, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialCrestone Inc. has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Yong Soo Chong has the most, with 1 of Crestone Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
